WO2006048266A2 - Profil d'expression genetique de leucemies a rearrangements geniques mll - Google Patents

Profil d'expression genetique de leucemies a rearrangements geniques mll Download PDF

Info

Publication number
WO2006048266A2
WO2006048266A2 PCT/EP2005/011732 EP2005011732W WO2006048266A2 WO 2006048266 A2 WO2006048266 A2 WO 2006048266A2 EP 2005011732 W EP2005011732 W EP 2005011732W WO 2006048266 A2 WO2006048266 A2 WO 2006048266A2
Authority
WO
WIPO (PCT)
Prior art keywords
mll
genes
expression
networks
cell
Prior art date
Application number
PCT/EP2005/011732
Other languages
English (en)
Other versions
WO2006048266A3 (fr
Inventor
Torsten Haferlach
Martin Dugas
Wolfgang Kern
Alexander Kohlmann
Susanne Schnittger
Claudia Schoch
Original Assignee
Roche Diagnostics Gmbh
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, F. Hoffmann-La Roche Ag filed Critical Roche Diagnostics Gmbh
Publication of WO2006048266A2 publication Critical patent/WO2006048266A2/fr
Publication of WO2006048266A3 publication Critical patent/WO2006048266A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des approches rapides et fiables de détection et de génotypage de leucémies. Plusieurs formes d'exécution concernent, par exemple, des procédés de génotypage de cellules de leucémies aiguës à t(11q23)/MLL. Outre ces procédés, l'invention concerne également des kits et des systèmes connexes.
PCT/EP2005/011732 2004-11-04 2005-11-03 Profil d'expression genetique de leucemies a rearrangements geniques mll WO2006048266A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62567304P 2004-11-04 2004-11-04
US60/625,673 2004-11-04

Publications (2)

Publication Number Publication Date
WO2006048266A2 true WO2006048266A2 (fr) 2006-05-11
WO2006048266A3 WO2006048266A3 (fr) 2006-08-24

Family

ID=36021847

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011732 WO2006048266A2 (fr) 2004-11-04 2005-11-03 Profil d'expression genetique de leucemies a rearrangements geniques mll

Country Status (1)

Country Link
WO (1) WO2006048266A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
CN109976760A (zh) * 2017-12-27 2019-07-05 北京东土科技股份有限公司 一种图形语言的交叉编译方法及交叉编译器
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002634A2 (fr) * 2000-06-30 2002-01-10 Incyte Genomics, Inc. Molécules de matrice extracellulaire et d'adhésion cellulaire
WO2002066954A2 (fr) * 2001-02-16 2002-08-29 Arbor Vita Corporation Interactions du domaine pdz et radeaux lipidiques
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies
WO2005043163A2 (fr) * 2003-11-04 2005-05-12 Roche Diagnostics Gmbh Methode pour distinguer des sous-types aml classes who

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002634A2 (fr) * 2000-06-30 2002-01-10 Incyte Genomics, Inc. Molécules de matrice extracellulaire et d'adhésion cellulaire
WO2002066954A2 (fr) * 2001-02-16 2002-08-29 Arbor Vita Corporation Interactions du domaine pdz et radeaux lipidiques
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies
WO2005043163A2 (fr) * 2003-11-04 2005-05-12 Roche Diagnostics Gmbh Methode pour distinguer des sous-types aml classes who

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAFERLACH T ET AL: "The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 100, no. 11, 16 November 2002 (2002-11-16), page 139A, XP002263227 ISSN: 0006-4971 *
KOHLMANN A ET AL: "MOLECULAR CHARACTERIZATION OF ACUTE LEUKEMIAS BY USE OF MICROARRAY TECHNOLOGY" GENES, CHROMOSOMES & CANCER, vol. 37, no. 4, August 2003 (2003-08), pages 396-405, XP008025253 *
KOHLMANN A ET AL: "Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients." LEUKEMIA : OFFICIAL JOURNAL OF THE LEUKEMIA SOCIETY OF AMERICA, LEUKEMIA RESEARCH FUND, U.K. JAN 2004, vol. 18, no. 1, January 2004 (2004-01), pages 63-71, XP002373717 ISSN: 0887-6924 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US10537560B2 (en) 2017-10-05 2020-01-21 Fulcrum Therapeutics. Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11291659B2 (en) 2017-10-05 2022-04-05 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11479770B2 (en) 2017-10-05 2022-10-25 Fulcrum Therapeutics, Inc. Use of p38 inhibitors to reduce expression of DUX4
CN109976760A (zh) * 2017-12-27 2019-07-05 北京东土科技股份有限公司 一种图形语言的交叉编译方法及交叉编译器

Also Published As

Publication number Publication date
WO2006048266A3 (fr) 2006-08-24

Similar Documents

Publication Publication Date Title
KR101530689B1 (ko) 직장결장암용 예후 예측
WO2006048262A2 (fr) Classification de la leucemie myeloblastique aigue
US9822417B2 (en) Methods and biomarkers for analysis of colorectal cancer
EP1996729A2 (fr) Analyse moléculaire pour prévoir une récidive du cancer du colon de stade dukes b
WO2010042228A2 (fr) Méthodes de prédiction d'évolution de maladie chez des patients souffrant d'un cancer du côlon
US20120004127A1 (en) Gene expression markers for colorectal cancer prognosis
WO2006048266A2 (fr) Profil d'expression genetique de leucemies a rearrangements geniques mll
WO2006048263A2 (fr) Profilage de l'expression genique dans la leucemie promyelocytique aigue
WO2006048264A2 (fr) Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0
WO2006048270A2 (fr) Procedes permettant de detecter une leucemie
WO2005043163A2 (fr) Methode pour distinguer des sous-types aml classes who
Nilbert et al. Lessons from genetic profiling in soft tissue sarcomas
WO2006048274A1 (fr) Profilage de l'expression du gene flt3
WO2006048273A1 (fr) Procedes de validation des tests d'expression genique
WO2006048265A2 (fr) Classification de leucemie avec translocation (9;22)
WO2006048275A2 (fr) Etablissement d'un profil d'expression pour la leucemie lymphocytaire chronique
US20070275380A1 (en) Method for Distinguishing Aml Subtypes With Aberrant and Prognostically Intermediate Karyotypes
WO2005043161A2 (fr) Procede pour faire la distinction entre des sous-types de leucemie
WO2005043164A2 (fr) Procede de differenciation entre les sous-types aml a cbf positif et les sous-types aml a cbf negatif
US20070122814A1 (en) Methods for distinguishing prognostically definable aml
US20070212734A1 (en) Method for Distinguishing T(11Q23)/Mll-Positive Leukemias From t(11Q23)/Mll Negative Leukemia
WO2005043167A2 (fr) Procede permettant de distinguer des sous-types de aml au moyen de divers dosages geniques
EP1682902A2 (fr) Procede pour faire la distinction entre l'aml mll-ptd-positive et d'autres sous-types d'aml

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05810753

Country of ref document: EP

Kind code of ref document: A2